Key Points - Rosen Law Firm reminds Capricor Therapeutics investors of the lead plaintiff deadline on September 29, 2026 - Kaplan Fox & Kilsheimer LLP announces a class action lawsuit against Capricor Therapeutics for securities fraud violations - Hagens Berman notifies investors of the lead plaintiff deadline in the pending securities class action against Capricor...
A 1.9% down gap appeared on Vaxart, Inc. (VXRT)'s chart — and the first question every...
Every position is an argument with someone on the other side. Here is what the numbers...
Citizens Community Bancorp, Inc. (CZWI) closed at $21.23 on 25,857 shares, -1.8% on the session.The close...
Motorcar Parts of America, Inc. (MPAA) gives both camps something to hold. These are the 2...
from RBC Capital issued a price target of $62.00 for BSVN on 2026-09-23 12:39:00.The adjusted price target was set to $62.00.At the time of the announcement, BSVN was trading at...
from Wedbush issued a price target of $50.00 for NKTR on 2026-09-23 11:45:04.The adjusted price target was set to $50.00.At the time of the announcement, NKTR was trading at $60.97.The...
from Guggenheim issued a price target of $12.00 for TLSI on 2026-09-23 10:54:00.The adjusted price target was set to $12.00.At the time of the announcement, TLSI was trading at $4.93.The...
from Stifel Nicolaus issued a price target of $12.00 for TLSI on 2026-09-23 10:54:00.The adjusted price target was set to $12.00.At the time of the announcement, TLSI was trading at...
Michael Schmidt from Guggenheim issued a price target of $4.00 for CMPX on 2026-09-23 10:42:00.The adjusted price target was set to $4.00.At the time of the announcement, CMPX was trading...
In a landscape marked by rapid technological advancements, the company saw a revenue increase of $1.4 million for the three months ending September 30, 2024, fueled by new licenses and...
In a landscape of fluctuating revenues, the company celebrated a 25% revenue increase in Q3 2024, yet faced a 14% decline over nine months due to production challenges. Operating expenses...
In a landscape marked by financial challenges, the company faced fluctuating revenues, with a notable 25% increase in Q3 2024 overshadowed by a 14% decline over nine months. Operating losses...
In a tale of growth and ambition, the company witnessed its revenue soar from $6.0 million to $13.9 million, fueled by partnerships with Acadia Pharmaceuticals. However, operating expenses, particularly in...
In a transformative period, the company experienced a remarkable surge in revenue, driven by newly acquired oil and gas assets. Operating expenses showed notable trends, with a decrease in occupancy...
